Treatment of HTLV-I-associated myelopathy with high-dose intravenous gammaglobulin
β Scribed by Y. Kuroda; H. Takashima; A. Ikeda; C. Endo; R. Neshige; R. Kakigi; H. Shibasaki
- Book ID
- 104719120
- Publisher
- Springer
- Year
- 1991
- Tongue
- English
- Weight
- 525 KB
- Volume
- 238
- Category
- Article
- ISSN
- 0340-5354
No coin nor oath required. For personal study only.
β¦ Synopsis
Fourteen patients with HTLV-1-associated myelopathy were treated with high-dose intravenous gammaglobulin (IVGG). Ten received 10 g/day of IVGG and 4 received 400 mg/kg of body-weight/day of IVGG for 5 consecutive days. Improvement of spastic paraparesis was observed in 10 within 7 days of the commencement of IVGG. The therapeutic effects were sustained for more than 3 weeks in some patients. There were no side effects. Analysis of factors of relevance to the clinical improvement with IVGG showed that the beneficial response was preferentially found in patients having a high CSF titre of anti-HTLV-I antibodies, a high CSF IgG level and a marked brain MRI abnormality.
π SIMILAR VOLUMES
The nucleotide sequence of human T-lymphotropic virus type I (HTLV-I) in central nervous system tissue was determined in 3 autopsy cases with HTLV-I-associated myelopathy (HAM)/tropical spastic paraparesis (TSP) and 1 seropositive carrier without HAM/TSP but with multiple sclerosis. All HAM/TSP samp